Compare AstraZeneca plc (AZN) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Halliburton Company — how do they compare? AstraZeneca plc trades at $166.69 (market cap $253.13B), while Halliburton Company trades at $35.52 (market cap $29.59B). The key difference: AstraZeneca plc is far larger — about 8.6× Halliburton Company's market cap, and Halliburton Company is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | HAL | |
|---|---|---|
Market Cap | $253.13B | $29.59B |
Sector | Health | Energy |
52-Week High | $209.48 | $42.98 |
52-Week Low | $137.44 | $20.50 |
Enterprise Value | $279.37B | $35.67B |
Dividend Yield | 1.92% | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Halliburton (HAL) trades at $35.21, up 2.38% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a major contract win offshore Suriname highlight operational strength, though net income declined in 2025. The stock shows solid profitability with a 6.95% net margin and 14.56% ROE, supported by positive cash flow trends into 2026.
The outlook remains positive given analyst targets near $44.78 and ongoing energy sector tailwinds, but risks include oil price volatility and execution challenges. Earnings growth and contract execution are key catalysts for further upside, balancing macroeconomic and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
